Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid-beta drugs in Alzheimer’s disease: a Bayesian meta-analysis

Aim: The use of amyloid-beta (Aβ) clearance to support regulatory approvals of drugs in Alzheimer’s disease (AD) remains controversial. We evaluate Aβ as a potential trial-level surrogate endpoint for clinical function in AD. Materials & methods: Data on the effectiveness of anti-Aβ monoclonal ant...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sa Ren, Janharpreet Singh, Sandro Gsteiger, Christopher Cogley, Ben Reed, Keith R Abrams, Dalia Dawoud, Rhiannon K Owen, Paul Tappenden, Terrence J Quinn, Sylwia Bujkiewicz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Becaris Publishing Limited 2025-12-01
coleção:	Journal of Comparative Effectiveness Research
Assuntos:	alzheimer’s disease amyloid-beta clinical outcomes meta-analysis surrogate endpoint
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!